PharmAla Biotech Holdings, Inc. (MDMA) Stock Price & Analysis

67 Followers

MDMA Stock Chart & Stats

CA$0.19CA$0.01(2.70%)

At close: Nov 03 4:00 PM EST

Day’s Range: CAD 0.19 - CAD 0.19
52-Week Range: CAD 0.09 - CAD 0.33
Previous Close: CAD 0.19
Volume: N/A
Average Volume (3M): 78.33K
Market Cap: CAD 20.21M
Enterprise Value: CAD 18.29M
Total Cash (Recent Filing): CAD 245.06K
Total Debt (Recent Filing): CAD 0
Price to Earnings (P/E): ―
Beta: -0.16
Next Earnings: Dec 18, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue growth shows that PharmAla is gaining commercial traction and increasing demand for its regulated products. If this expansion continues, greater scale could improve operating leverage, support reinvestment in the business, and strengthen its position in clinical and research supply markets.

Debt-Free Balance Sheet

The absence of reported debt gives PharmAla greater financial flexibility than a similarly loss-making company carrying substantial leverage. With no meaningful interest burden or debt refinancing obligation, more future capital can be directed toward operations, product development, and commercial expansion.

Positive Equity And Asset Base

Positive equity and a meaningful asset base provide some support for the company while it remains early stage. This foundation may help sustain regulated production and development activities, and offers greater resilience than a balance sheet already impaired by negative equity.

Bears Say

Persistent Operating Losses

Negative gross profit and deeply negative operating earnings indicate that current revenue does not yet cover the cost structure. Without material improvement in pricing, product mix, or operating efficiency, revenue growth may continue to require external funding rather than translate into durable profitability.

Negative Cash Generation

Cash burn of roughly $0.97 million over the trailing period means operations are consuming capital rather than self-funding growth. Continued negative free cash flow can constrain investment capacity and make financing needs persistent unless revenue scales materially or operating costs decline.

Negative Returns And Erosion Risk

A deeply negative return on equity shows that the existing capital base is not yet producing profitable returns. If losses persist, the company may erode equity or depend on additional capital, potentially increasing dilution and limiting the resources available for long-term growth.

PharmAla Biotech Holdings, Inc. News

PharmAla taps Rua Bioscience to launch GMP-grade MDMA in New Zealand

The latest announcement is out from PharmAla Biotech Holdings, Inc. ( ($TSE:MDMA) ). Rua Bioscience and PharmAla Biotech have signed a distribution and licence agreement that will see Rua import

3w agoMDXXF MDMA

PharmAla Biotech Overhauls Auditor and Bolsters Investor Outreach

PharmAla Biotech Holdings, Inc. ( ($TSE:MDMA) ) just unveiled an announcement. PharmAla Biotech has appointed Davidson & Company LLP as its new auditor after Clearhouse LLP declined a proposed U.S.

1M agoMDXXF MDMA

PharmAla Biotech Wins U.S. Patent, Retains APA-01 Rights and Hires Canaccord

PharmAla Biotech Holdings, Inc. ( ($TSE:MDMA) ) has issued an announcement. PharmAla Biotech has secured a U.S. patent covering novel processes for manufacturing single enantiomers of MDMA and MBDB, a

2M agoMDXXF MDMA

Psychedelic: Clearmind reports safety findings for CMND-100

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on safety results, earnings and analyst initiations. CLEARMIND REPORTS SAFETY FINDINGS FOR CMND-100:

3M agoCMND CMPS

PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year

“PharmAla’s (MDXXF) financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick Kadysh, CEO, PharmAla Biotech. “We were pleased to

3M agoMDXXF MDMA

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a license agreement, enrollment completion and a patent filing. PHARMALA, JUPITER ENTER

3M agoLLY ATAI

PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences

PharmAla (MDXXF) announced that it has entered into a definitive license agreement on July 20 with Jupiter Neurosciences (JUNS), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license

3M agoJUNS MDXXF

Psychedelic: Compass Pathways reports six-month data for psilocybin drug

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS

3M agoATAI CMND

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, the signing of a term sheet and a research agreement .

5M agoCMND CMPS

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a treatment update and an analyst initiation. EARNINGS: On Thursday, GH

5M agoATAI CMND

Psychedelic: FDA awards Compass Pathways priority review voucher

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a BTD evaluation, granting of a priority review voucher and a collaboration

6M agoCMND CMPS

PharmAla positioned to supply U.S. expanded access pathway for MDMA

PharmAla (MDXXF) Biotech responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration and the

6M agoMDXXF MDMA

Psychedelic: Compass Pathways, NRx Pharma report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, publications of study results and MDMA commercialization. COMPASS PATHWAYS REPORTS Q4

7M agoATAI CMPS

Cortexa Deepens Lead in Australia’s MDMA Market With New GMP Supply and Expanded Access

The latest update is out from PharmAla Biotech Holdings, Inc. ( ($TSE:MDMA) ). Cortexa, a 50/50 joint venture between PharmAla Biotech and Vitura Health, has reinforced its leadership in Australia’s

7M agoMDXXF MDMA

MDMA FAQ

What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?

PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.33 in the past 12 months.

What is PharmAla Biotech Holdings, Inc.’s market cap?

PharmAla Biotech Holdings, Inc.’s market cap is C$20.21M.

When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?

PharmAla Biotech Holdings, Inc. released its earnings results on Jul 29, 2026. The company reported -C$0.005 earnings per share for the quarter.

Is PharmAla Biotech Holdings, Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does PharmAla Biotech Holdings, Inc. pay dividends?

PharmAla Biotech Holdings, Inc. does not currently pay dividends.

What is PharmAla Biotech Holdings, Inc.’s EPS estimate?

PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmAla Biotech Holdings, Inc. have?

PharmAla Biotech Holdings, Inc. has 109,236,030 shares outstanding.

What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?

PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.005 in its last earnings report. Following the earnings report the stock price went up 6.667%.

Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?

Currently, no hedge funds are holding shares in TSE:MDMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description